This new process focuses on identifying gene expression pathways associated with proteinuria reduction in proteinuric disease and auspicious pathways associated with proteinuria reduction, enabling rational repurposing of existing drugs and informing development of novel, non‑immunosuppressive treatments for INS and other proteinuric glomerular diseases.